Evidence map›Paper›PMID 37039902›Full record

ArticleJournal of cancer research and clinical oncology2023

A prognostic and immunological analysis of 7B-containing Kelch structural domain (KLHDC7B) in pan-cancer: a potential target for immunotherapy and survival.

Jiatong Ding, Xunhui Ji, Lanqi Liu, De-Zhi Chen, Nan Luo, Xiao-Ting Yu, Fei Guo

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jiatong Ding *Ningbo Institute for Medicine & Biomedical Engineering Combined Innovation, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, 315000, China.
Xunhui Ji *Ningbo Institute for Medicine & Biomedical Engineering Combined Innovation, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, 315000, China.
Lanqi LiuNingbo Institute for Medicine & Biomedical Engineering Combined Innovation, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, 315000, China.
De-Zhi ChenNingbo Institute for Medicine & Biomedical Engineering Combined Innovation, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, 315000, China.
Nan LuoNingbo Institute for Medicine & Biomedical Engineering Combined Innovation, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, 315000, China.
Xiao-Ting YuDepartment of Breast Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, 330000, China.
Fei Guo *Ningbo Institute for Medicine & Biomedical Engineering Combined Innovation, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, 315000, China. guofei2005@126.com.
Ningbo University · CNFirst Affiliated Hospital of Nanchang University · CNNingbo Medical Center Lihuili Hospital · CN

Funding

National Natural Science Foundation of China 81772083 (GF)National Natural Science Foundation of China 81860342National Natural Science Foundation of China 81972445
6 · The paper itself

Abstract

purposeKLHDC7B is a member of Kelch family, with a Kelch domain in the C-terminal half, which plays a role in various cellular events, such as cytoskeletal arrangement, protein degradation, gene expression. Although there is increasing evidence supporting KLHDC7B's vital role in tumorigenesis, a systematic analysis of KLHDC7B in cancers remains lacking. Therefore, we intended to investigate the prognostic value for KLHDC7B across 33 cancer types and explore its potential immunological function.

methodsGEO (Gene Expression Omnibus database) and TCGA (The Cancer Genome Atla) database were used to explore the role of KLHDC7B in 33 cancers. TIMER2, GEPIA2 and Kaplan-Meier plotter were utilized to explore the KLHDC7B expression level and prognostic value in different cancers. The pan cancer genetic variation and DNA methylation of KLHDC7B were analyzed by cBioPortal and MEXPRESS. TIMER2 was employed to investigate the correlation between KLHDC7B expression and immune infiltration. The relationship of KLHDC7B expression with TMB (tumor mutational burden) and MSI (microsatellite instability) were evaluated using Spearman correlation analysis. Finally, by GO and KEGG enrichment analysis, the underlying mechanisms of KLHDC7B in tumor pathophysiology were further investigated.

resultsKLHDC7B expression level was related to pathological stages, MSI, TMB, immune checkpoint and immune cell infiltration in most cancers. Especially, we found that the KLHDC7B expression was negatively correlated with the immune infiltration of Myeloid derived suppressor cells into TGCT and GBM. Additionally, survival analysis showed that the expression of KLHDC7B was connected with overall survival (OS) in 3 cancers and disease-free survival (DFS) in 5 cancers. Furthermore, the enrichment analysis revealed that the KLHDC7B collecting genes and binding proteins are related to the function of proteins and immune response.

conclusionKLHDC7B demonstrates strong clinical utility as markers of prognostic and immune response in pan-cancer.

Indexed as

Kelch RepeatNeoplasmsCarcinogenesisHumansImmunotherapyMicrosatellite InstabilityPrognosisBiomarkerKLHDC7BPan-cancerPrognosisTumor immunity

Identifiers

PMID37039902
PMCPMC11796585
OpenAlexW4364352647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.